Arrowhead Pharmaceuticals Inc. (ARWR)

31.19
NASDAQ : Health Technology
Prev Close 29.18
Day Low/High 29.30 / 31.56
52 Wk Low/High 10.41 / 30.73
Avg Volume 1.96M
Exchange NASDAQ
Shares Outstanding 95.30M
Market Cap 2.78B
EPS -0.70
P/E Ratio 63.43
Div & Yield N.A. (N.A)
8 Penny Stocks Get Delisting Warning

8 Penny Stocks Get Delisting Warning

Another round of small-cap companies are on watch by the Nasdaq and NYSE to be delisted in six months.

Arrowhead Research CEO Discusses F4Q2010 Results – Earnings Call Transcript

Arrowhead Research CEO Discusses F4Q2010 Results – Earnings Call Transcript

Arrowhead Research CEO Discusses F4Q2010 Results â¿¿ Earnings Call Transcript

Arrowhead Reports Fiscal 2010 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2010 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 fourth quarter and year ended September 30, 2010.

Arrowhead Starts New Subsidiary, Ablaris Therapeutics, To Commercialize Anti-Obesity Technology

Arrowhead Starts New Subsidiary, Ablaris Therapeutics, To Commercialize Anti-Obesity Technology

Arrowhead Research Corporation (NASDAQ: ARWR) (“Arrowhead” or the “Company”) today announced that it has executed an exclusive world-wide license on technology developed by Drs.

Arrowhead Research To Report Fiscal 2010 Fourth Quarter And Year-End Financial Results And Host Conference Call On Wednesday, December 22, 2010

Arrowhead Research To Report Fiscal 2010 Fourth Quarter And Year-End Financial Results And Host Conference Call On Wednesday, December 22, 2010

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2010 fourth quarter and year ended September 30, 2010, on Wednesday, December 22, 2010 at 4:30 p.

Arrowhead CEO Provides Perspective On $4.5 Million Alliance Between Subsidiary Unidym And Samsung Electronics

Arrowhead CEO Provides Perspective On $4.5 Million Alliance Between Subsidiary Unidym And Samsung Electronics

Arrowhead Research Corporation’s (NASDAQ: ARWR) (“the Company”) President and Chief Executive Officer today issued the following open letter to the Company’s shareholders: Dear...

Unidym Announces Alliance With Samsung Electronics

Unidym Announces Alliance With Samsung Electronics

Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has completed IP cooperation and license agreements with Samsung Electronics Co.

BBC Broadcasts Interview With Dr. Samuel Stupp, Founder Of Arrowhead Portfolio Company, Nanotope, Inc.

BBC Broadcasts Interview With Dr. Samuel Stupp, Founder Of Arrowhead Portfolio Company, Nanotope, Inc.

An interview with Dr. Sam Stupp, founder and scientific advisor to Nanotope, Inc.

Arrowhead Strengthens Board Of Directors With The Appointment Of Dr. Douglass Given

Arrowhead Strengthens Board Of Directors With The Appointment Of Dr. Douglass Given

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Douglass Given MD, PhD, MBA, has joined the Company’s Board of Directors, expanding Arrowhead’s Board to a total of six directors.

Arrowhead Portfolio Companies, Calando Pharmaceuticals, Inc. And Nanotope, Inc., Awarded Federal Grants To Advance Therapeutics

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its portfolio companies, Calando Pharmaceuticals, Inc.

Arrowhead To Present At Oppenheimer 21st Annual Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr.

Arrowhead Portfolio Company, Nanotope, Inc. Enters Agreement With Smith & Nephew For The License And Development Of Cartilage Regeneration Technology

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its portfolio company, Nanotope, Inc.

Arrowhead CEO Provides Update On Company Strategy And Milestone Achievements

Arrowhead Research Corporation’s (NASDAQ: ARWR) (“the Company”) President and Chief Executive Officer today issued the following open letter to the Company’s shareholders: Dear...

Arrowhead To Present At 9th Annual Bio Investor Forum

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that Dr.

Arrowhead Increases Ownership In RNAi Subsidiary Calando Pharmaceuticals, Inc.

Arrowhead Research Corporation (NASDAQ:ARWR) (“the Company”) today announced that it has increased its ownership of majority owned subsidiary Calando Pharmaceuticals through the exchange of Calando Series...

Arrowhead To Present At Rodman & Renshaw Annual Global Investment Conference

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr.

Arrowhead Research Appoints Dr. Mauro Ferrari To Its Board Of Directors

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr.

Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript

Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript

Arrowhead Reports Fiscal 2010 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced financial results for its fiscal 2010 third quarter ended June 30, 2010.

Arrowhead Options Obesity-Fighting Technology From MD Anderson Cancer Center

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of...

Arrowhead Research To Report Third Quarter Fiscal 2010 Financial Results And Host Conference Call On Thursday, August 12, 2010

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2010 third quarter ended June 30, 2010, on Thursday, August 12, 2010, at 4:30 p.

Arrowhead Announces Closing Of $8.65 Million Registered Direct Offering

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has closed its previously announced registered direct offering of 6.

Arrowhead Announces Offering Of Common Stock And Warrants

Arrowhead Announces Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced and received firm commitments for a registered direct offering to raise $8.

Arrowhead To Hold Annual Meeting June 16, 2010; CEO Presentation Available Via Webcast

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Annual Meeting of Stockholders will be held on Wednesday, June 16, 2010 at 10:00 am PT at the Sheraton Pasadena, 303 E.

Arrowhead To Rejoin The Russell Microcap Index

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will join the Russell Microcap® Index when Russell Investments reconstitutes its family of U.

Arrowhead Portfolio Company, Leonardo Biosystems, Receives $2.5 Million Funding From Texas Emerging Technology Fund

Arrowhead Research Corporation (Nasdaq: ARWR) announced today that its portfolio company, Leonardo Biosystems, has received a $2.

Unidym And Tokyo Electron Begin Joint Program To Develop Large Scale Manufacturing Equipment For Printable Carbon Nanotube-Based Displays And Solar Cells

Unidym, a majority owned subsidiary of Arrowhead Research (NASDAQ:ARWR) announced today that it has finalized an agreement with Tokyo Electron (TEL) to develop manufacturing equipment for carbon nanotube based...

Mediacom, Jones Soda: Midday Volume Plays

Several stocks trading near $5, including Mediacom Communications, were moving on above-average volume Tuesday.

Arrowhead Research Announces Clinical Data Presentations At The 2010 ASCO Annual Meeting On June 6, 2010

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that interim data from the phase 1 clinical trial conducted by its majority-owned subsidiary, Calando Pharmaceuticals, will be presented at the 2010...

Arrowhead To Present At Noble Financial Sixth Annual Equity Conference

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr.

TheStreet Quant Rating: C+ (Hold)